Free Republic

I urgently prompted my Dr. for more than 1 year for prevention and treatment protocols for possibly imminent, high lethality viruses. She's a good Dr. but her training gets in the way of giving a straight answer. The following very simple elements use 1) an inexpensive Dr. Z. protocol, 2) saline and very dilute hydrogen peroxide administered via home nebulizer, and 3) low-dose lithium from Dr. Michael Nehls. The protocol of the late Dr. Zev Zelenko, with which he suffered only 1 demise among 7,000 patients, uses Vitamin D, zinc, quercetin to substitute for hydroxychloroquine (generally unavailable because prescription only)...

The COVID-19 antiviral drug Molnupiravir helps speed up recovery from the virus but does not reduce the hospitalization or death rate in higher-risk vaccinated adults, a new study has found.Molnupiravir, from Ridgeback Biotherapeutics and Merck & Co. is used to treat mild to moderate COVID-19 and can be taken at home, twice a day for five days, within five days of symptoms onset.It works by stopping the virus from replicating, keeping levels low in the body, thus reducing its severity.The study was published in The Lancet on Dec. 22 and has been peer reviewed.Between Dec. 8, 2021 and April 27,...

Brief Summary: The CDC and WHO have deemed the COVID-19 virus a global pandemic of unprecedented severity in modern times. In 2019, this novel Coronavirus (COVID-19) emerged from the Asian continent and has now caused upwards of 1million deaths and over 6 million infections globally. Currently, the estimated global economic impact is over 5 Trillion dollars. Understanding the host response to pathogens, specifically the cellular and humoral responses, has played an important role in new non-antibiotic therapies. Bismuth subsalicylate (Pepto-Bismol) has a potential role in the clearance and/or recurrence of enteric viral infections.

Extracts from blueberries and blackcurrants prevent infection by measles and herpes viruses in cell cultures. Würzburg researchers were very surprised by this. The study used herpes and measles viruses modified in that way that infected cells fluoresce green. Substances inhibiting infection by viruses thus caused fewer cells to glow green under UV light. The number of infected cells in the cultures could thus be managed by automated counting. Nine active ingredient candidates were added to the cell systems and the effect on the infection process was investigated. The data collected show that a mixture of extracts of blackcurrants and blueberries...

Vice President Kamala Harris has been prescribed and has taken Paxlovid, an antiviral pill used to treat COVID-19. Harris’s press secretary Kirsten Allen tweeted the announcement about the vice president’s treatment on Tuesday. It came just hours after it was announced that Harris, who is fully vaccinated and boosted, tested positive for COVID-19.

Joe Rogan said something interesting in his Instagram post the other day when he was responding to the Spotify controversy about his podcasts. He talked about his view on the media attacking him for “misinformation.”“The problem I have with the term misinformation – especially today – is that many of the things that we thought of as misinformation just a short while ago are now accepted as fact, like for instance, if you said eight months ago, you can still catch COVID, and you can still spread COVID, you’d be removed from social media. They would ban you from certain...

Pfizer’s antiviral oral drug developed to treat COVID-19 can cause severe or life-threatening effects when used with common medications including some anti-coagulants, some anti-depressants, and some cholesterol-lowering statins, according to the Food and Drug Administration (FDA) (pdf). FDA does not recommend Paxlovid for those with severe kidney or liver disease.The FDA on Dec. 22 granted emergency use authorization (EUA) to Pfizer’s COVID-19 treatment pill as treatment for mild-to-moderate cases of COVID-19 in patients from 12 years of age.Paxlovid was the first oral medication of its kind authorized by the FDA to treat COVID-19, with the aim of reducing the need...

Abstract Viruses such as human cytomegalovirus (HCMV), human papillomavirus (HPV), Epstein–Barr virus (EBV), human immunodeficiency virus (HIV), and coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) represent a great burden to human health worldwide. FDA‐approved anti‐parasite drug ivermectin is also an antibacterial, antiviral, and anticancer agent, which offers more potentiality to improve global public health, and it can effectively inhibit the replication of SARS‐CoV‐2 in vitro. This study sought to identify ivermectin‐related virus infection pathway alterations in human ovarian cancer cells. Stable isotope labeling by amino acids in cell culture (SILAC) quantitative proteomics was used to analyze human ovarian cancer...

On the latest episode of “The Jimmy Dore Show,” comedian and political commentator Jimmy Dore highlighted the similarities between Pfizer’s expensive new antiviral drug for COVID and ivermectin, a generic drug used to treat the virus.“I’ve never seen the propaganda machine so hard at work as it’s been against ivermectin,” said Dore. “Ivermectin won a Nobel Prize for human medicine in 2015, but the media really has everyone believing it’s for horses.” Dore suggested the motivation behind the propaganda is profits.Dore played a video of John Campbell, Ph.D., explaining how Pfizer’s antiviral and ivermectin treat COVID in “the exact same...

Masitinib, an existing drug used to treat tumors in animals, may be an effective treatment against many types of coronaviruses, including the one that causes COVID-19. _______________________________________________________________________________________________________ Scientists using the Advanced Photon Source have discovered that a drug used to fight tumors in animals might be effective against many types of coronaviruses, including SARS-CoV-2. Scientists from the University of Chicago have found that the drug masitinib may be effective in treating COVID-19. The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2, the virus that...

AbstractBackground There are limited antiviral options for the treatment of patients with COVID-19. Ivermectin (IVM), a macrocyclic lactone with a wide anti-parasitary spectrum, has shown potent activity against SARS-CoV-2 in vitro. This study aimed at assessing the antiviral effect of IVM on viral load of respiratory secretions and its relationship with drug concentrations in plasma. Methods Proof-of-concept, pilot, randomized, controlled, outcome-assessor blinded trial to evaluate antiviral activity of high-dose IVM in 45 COVID-19 hospitalized patients randomized in a 2:1 ratio to standard of care plus oral IVM at 0·6 mg/kg/day for 5 days versus standard of care in 4 hospitals...

New insights into the mode of action of ivermectin against the novel SARS coronavirus.The previously discussed, WHO-sponsored meta-analysis of ivermectin against covid-19 has now been published as a preprint. It found a highly significant 75% reduction in covid mortality, based on randomized controlled trials only, and will be continually updated with additional trial results.To date, the mode of action of ivermectin against SARS-CoV-2 has remained somewhat of a mystery. Early studies indicated that ivermectin may inhibit viral protein transportation. But a new US-Canadian study, published in Nature Communications Biology, found that ivermectin is highly effective (>90%) in inhibiting the main...

A University of Alberta virology lab has uncovered how an oral antiviral drug works to attack the SARS-CoV-2 virus, in findings published May 10 in the Journal of Biological Chemistry. The researchers demonstrated the underlying mechanism of action by which the antiviral drug molnupiravir changes the viral genome, a process known as excessive mutagenesis or "error catastrophe.""The polymerase, or replication engine of the virus, mistakes molnupiravir molecules for the natural building blocks required for viral genome replication and mixes them in," explained Matthias Götte, professor and chair of the Department of Medical Microbiology & Immunology in the Faculty of Medicine...

NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 RADNOR, Pa., March 29, 2021 /PRNewswire/ -- NeuroRx, Inc. today reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG (SIX:RLF,OTCQB:RLFTF). Across all patients and sites, ZYESAMI™ met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013) and...

This article was translated from our Spanish edition using AI technologies. Errors may exist due to this process.The COVID-19 vaccine may spell the end of the pandemic, but while mass vaccination is not available it is vital to stop community transmission. The new antiviral drug MK-4482 / EIDD-2801 or Molnupiravir, has managed to suppress "completely" the transmission of the coronavirus in just 24 hours , according to studies by the Institute of Biomedical Sciences of Georgia State University. "This is the first demonstration of an orally available drug that quickly blocks the transmission of SARS-CoV-2 , so it could be...

Researchers at Case Western Reserve University have added to the growing body of understanding about how hydroxychloroquine (HCQ) is not a possible defense against COVID-19. Specifically, they found that HCQ is not effective in preventing COVID-19 in patients with lupus and rheumatoid arthritis (RA), suggesting a broader interpretation of HCQ as ineffective preventive medicine for the general population. Their findings were recently published in the Annals of the Rheumatic Diseases. Many researchers have focused on patients with systemic lupus erythematosus (SLE) and RA because HCQ is frequently taken by these patients. Anecdotal reports in the early stages of the pandemic...

FDA Lets NeuroRx, Relief Therapeutics Test RLF-100 in COVID-19 PatientsZURICH — The U.S. Food and Drug Administration has granted NeuroRx Inc Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 to prevent progression to respiratory failure, it and partner Relief Therapeutics Holdings said on Thursday. ... They said aviptadil is shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes while also preventing synthesis of cytokines in the lung. ... has been granted FDA fast track designation, FDA emergency use IND...

NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19 Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients. At FDA's request, NeuroRx is submitting an expanded access policy enabling physicians to request RLF-100 for patients who meet this criterion. June 24, 2020 01:30 AM Eastern Daylight Time RADNOR, Pa. & GENEVA--(BUSINESS WIRE)--NeuroRx, Inc. (OTC:RLFTF), in partnership with RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” today announced that...

ABSTRACT Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. In the absence of a known efficient therapy and because of the situation of a public-health emergency, it made sense to...

The first COVID-19 vaccine in China is expected to be ready for clinical trials by the end of April, according to Xu Nanping, China’s vice-minister of science and technology. Inovio Pharmaceuticals plans to begin clinical trials on a coronavirus vaccine in April this year. Health officials from WHO have noted that Gilead’s remdesivir has demonstrated efficacy in treating the coronavirus infection. Chloroquine approved for emergency use by US FDA The US Food and Drug Administration (FDA) approved limited emergency use for chloroquine and hydroxychloroquine as a treatment for COVID-19. The President of the United States, Donald Trump, had announced on...